Table 2

Estimated screening-related resource use and health outcomes by year and screening scenario: biennial gFOBT at 55–74 years, biennial FIT at 55–74 years, and FSIG once at 60 years
Year of programme Year 1 Year 10
Screening scenario gFOBT FIT FSIG gFOBT FIT FSIG
Screening-related resource use
Screening tests No. of kits sent out 357,812 357,812 420,151 417,464
No. of kits processed 189,640 189,640 222,637 220,999
No. of FSIG done1 18,617 20,625
COL/CTC No. of diagnostic COL 967 11,095 381 1,103 12,414 423
No. of diagnostic CTC 126 1,442 50 143 1,614 55
No. of surveillance COL 0 0 0 297 2,406 620
No. of surveillance CTC 0 0 0 39 313 81
Pathology No. of adenomas and CRCs requiring pathology2 1,004 7,161 1,599 1,356 8,909 2,222
CRC work-up and treatment No. receiving PET scan 31 85 6 34 69 8
No. receiving MRI scan 111 307 23 121 247 28
No. receiving CT scan(s) 309 853 64 336 687 78
No. receiving TUS 16 43 3 17 35 4
No. receiving pre-operative radiotherapy3 71 196 15 75 146 17
No. undergoing colorectal resection4 281 779 59 307 635 71
Screening-related health outcomes
Harms5 No. with major bleeding following endoscopy 4 48 7 6 62 10
No. with perforation following endoscopy 2 21 1 2 27 2
No. of deaths from perforation following endoscopy 0 1 0 0 1 0
Screen-detected lesions No. with adenoma(s)6 Total 366 3,320 808 537 4,327 1,128
  low-risk 229 2,081 544 333 2,770 740
  intermediate/high-risk 137 1,239 264 204 1,558 388
No. with CRC7 Total 309 853 64 336 687 78
  stage I 111 308 23 130 303 31
  stage II 105 293 22 115 237 26
  stage III 69 192 14 68 115 16
  stage IV 24 60 4 23 31 5

COL colonoscopy, CRC colorectal cancer, CTC CT colonography, gFOBT guaiac-based faecal occult blood test, FIT faecal immunochemical test, FSIG flexible sigmoidoscopy, TUS ultrasound; intermediate/high-risk = adenoma(s) ≥10 mm; low-risk = adenoma(s) <10 mm;

1 includes FSIG with and without polypectomy.

2 sum of number of adenomas and colorectal cancers requiring pathology, assuming average of 1.9 adenomas per person; includes screen-detected and surveillance-detected adenomas.

3 applies to rectal cancer only; includes radiotherapy given with or without chemotherapy.

4 sum of estimates of colon and rectal resections required.

5 includes complications from diagnostic and surveillance endoscopy, including FSIG where relevant.

6 includes individuals with screen-detected and surveillance-detected adenomas.

7 includes individuals with CRC detected at screening and at surveillance.

Sharp et al.

Sharp et al. BMC Health Services Research 2013 13:105   doi:10.1186/1472-6963-13-105

Open Data